Research graph
References from Chimeric antigen receptor T-cell therapy for refractory post-transplant lymphoproliferative disorder after lung transplantation. Local targets link to admitted publications; unresolved targets remain external evidence.
Real-world evidence of the safety and survival with CD19 CAR-T cell therapy for relapsed/refractory solid organ transplant-related PTLD
10.1111/bjh.18828 · 2023 · External reference
CAR-T therapy in solid organ transplant recipients with treatment refractory posttransplant lymphoproliferative disorder
10.1111/ajt.16367 · 2021 · External reference
ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells
10.1016/j.bbmt.2018.12.758 · 2019 · External reference
Autologous stem cell transplantation for post-transplant lymphoproliferative disorders after solid organ transplantation: a retrospective analysis from the Lymphoma Working Party of the EBMT
10.1038/s41409-021-01270-5 · 2021 · External reference
Survival with axicabtagene ciloleucel in large b-cell lymphoma
10.1056/nejmoa2301665 · 2023 · External reference
Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia
10.1126/scitranslmed.3008226 · 2014 · External reference
Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma
10.1182/blood.2020008865 · 2021 · External reference
